NASDAQ
12.08.25 | 21:58
1,415 US-Dollar
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.08. | Zentalis Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 01.07. | Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 68 | GlobeNewswire (Europe) | SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1... ► Artikel lesen | |
| ZENTALIS PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 18.06. | Aktionäre von Zentalis Pharmaceuticals wählen drei Direktoren bei Jahreshauptversammlung | 3 | Investing.com Deutsch | ||
| 18.06. | Zentalis Pharmaceuticals, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 02.06. | Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 66 | GlobeNewswire (Europe) | SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1... ► Artikel lesen | |
| 02.06. | Zentalis Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.05. | Zentalis Pharmaceuticals, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 14.05. | Zentalis Pharmaceuticals GAAP EPS of -$0.67 misses by $0.04 | 1 | Seeking Alpha | ||
| 14.05. | Zentalis Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 01.05. | Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 118 | GlobeNewswire (Europe) | SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1... ► Artikel lesen | |
| 28.04. | Zentalis Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 23.04. | Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 01.04. | Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 124 | GlobeNewswire (Europe) | SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1... ► Artikel lesen | |
| 27.03. | Stifel maintains Buy on Zentalis stock with $9 target | 2 | Investing.com | ||
| 27.03. | H.C. Wainwright sets $10 target for Zentalis shares, maintains Buy | 1 | Investing.com | ||
| 26.03. | Zentalis Pharmaceuticals GAAP EPS of -$2.33 beats by $0.13, revenue of $67.43M beats by $26.81M | 3 | Seeking Alpha | ||
| 26.03. | Zentalis Pharmaceuticals files $250M mixed securities shelf | 1 | Seeking Alpha | ||
| 26.03. | Zentalis Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 26.03. | Zentalis Pharmaceuticals, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 26.03. | Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates | 141 | GlobeNewswire (Europe) | Positive azenosertib clinical data demonstrated clinically meaningful results in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) Topline data from registration-intent DENALI Part... ► Artikel lesen |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CUREVAC | 4,712 | +0,04 % | Biontech und Curevac beenden Patentstreit | MAINZ/TÜBINGEN (dpa-AFX) - Vor der angekündigten Übernahme von Curevac durch den deutschen Konkurrenten Biontech haben die beiden Unternehmen aus Tübingen und Mainz ihren Patentstreit um Corona-Impfstoff-Patente... ► Artikel lesen | |
| MODERNA | 22,015 | +0,18 % | Health Secretary Cancels $500m Moderna Vaccine Funding As Data Show Its Failure Against Covid | WASHINGTON (dpa-AFX) - The US Department of Health and Human Services has announced that it is winding down the mRNA vaccine development activities under the Biomedical Advanced Research and... ► Artikel lesen | |
| VALNEVA | 4,404 | +10,82 % | Valneva: FDA gibt Chikungunya-Impfstoff IXCHIQ wieder frei | Valneva hat bekanntgegeben, dass die US-Arzneimittelbehörde FDA die zuvor empfohlene Einschränkung für den Chikungunya-Impfstoff IXCHIQ bei Personen ab 60 Jahren aufgehoben hat. Zugleich wurde eine... ► Artikel lesen | |
| NOVAVAX | 7,200 | -0,35 % | Novavax, Inc.: Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights | Total revenue of $239 million in the second quarter of 2025
Received FDA BLA approval for Nuvaxovid, the only recombinant protein-based, non-mRNA COVID-19 vaccine... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,490 | +2,73 % | NurExone Biologic: Unfassbarer Erfolg der präklinischen Studie! | ||
| CARDIFF ONCOLOGY | 2,100 | +0,72 % | A Glimpse Into The Expert Outlook On Cardiff Oncology Through 4 Analysts | ||
| IMMUNITYBIO | 2,075 | -1,75 % | ImmunityBio, Inc.: ImmunityBio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, With Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-code | Q2 2025 Revenue Growth with Continued Strong Sales Momentum: $26.4 million, up 60% from Q1 2025, with year-to-date sales of approximately $43 million.
ANKTIVA Unit Growth Since J-code:... ► Artikel lesen | |
| ALDEYRA | 4,518 | -1,50 % | Jones Trading erhöht Kursziel für Aldeyra nach FDA-Annahme auf 9 US-Dollar | ||
| IOVANCE BIOTHERAPEUTICS | 1,931 | +0,40 % | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025 | $60.0M in 2Q25 Total Product Revenue More than 100 Patients Treated with Amtagvi® in 2Q25 Strategic Restructuring Extends Cash Runway into 4Q26 FY25 Total Product Revenue Guidance of $250M-$300M Reiterated... ► Artikel lesen | |
| COHERUS ONCOLOGY | 0,759 | -3,02 % | Coherus Oncology, Inc.: Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update | - LOQTORZI net revenue was $10.0 million, a 36% increase over Q1 2025 - - Data readouts for CHS-114 and casdozokitug on track for 1H 2026 - - Q2 2025 ending cash, cash equivalents and marketable... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 10,660 | -0,23 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company | BEDFORD, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular"), a biopharmaceutical company committed to redefining the retina experience, announced the launch... ► Artikel lesen | |
| GUARDANT HEALTH | 47,360 | +0,38 % | Exact Sciences Teams Up With Freenome to Take on Guardant Health in Colorectal Cancer Screening | ||
| ESPERION | 1,501 | -2,41 % | Esperion Therapeutics, Inc.: Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | ANN ARBOR, Mich., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on August 5, 2025, the Company granted 12 new employees 73,500 restricted stock units (RSUs) under... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 2,828 | -2,75 % | Voyager Therapeutics, Inc.: Voyager Reports Second Quarter 2025 Financial and Operating Results | - Cash runway extended into 2028; expected to enable multiple meaningful clinical data read-outs - - APOE program added to pipeline; fourth asset in industry-leading Alzheimer's disease franchise... ► Artikel lesen | |
| OPGEN | 2,600 | 0,00 % | NSE - OPGEN INC - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities |
ZENTALIS PHARMACEUTICALS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,415 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ZENTALIS PHARMACEUTICALS INC finden Sie auf Wallstreet Online.